Table 1 Overview of Nrf2-interacting factors in cancer cell lines
From: Targeting Nrf2 may reverse the drug resistance in ovarian cancer
Gene | Effects on Nrf2 | Effects on cell | Tumor model | Resistance to | References |
|---|---|---|---|---|---|
P62 | Activator | Protective | SKOV3/DDP | Cisplatin | [48] |
CD99 | Activator | Protective | A2780,COC1/DDP | Cisplatin | |
ABCF2 | Activator | Protective | A2780 | Cisplatin | [52] |
ATF2 | Inhibitor | Cytotoxic | SKOV3 | Cisplatin | [53] |
AKR1C1 | Activator | Protective | – | Platinum | [54] |
SIRT5 | Activator | Protective | A2780,SKOV3,CAOV3 | Cisplatin | [55] |
SLC40A1 | Inhibitor | Cytotoxic | A2780CP,PEO4,COC1/DDP | Cisplatin | [56] |
HER1 | Activator | Protective | PEO1, SKOV3, and OVCAR3 | lapatinib and erlotinib | [82] |
HER2/HER3 | Activator | Protective | PEO4,OVCAR4,SKOV3 | Pertuzumab/Trastuzumab/Docetaxel | [80] |
ABCG2 | Activator | Protective | SKOV3 | Mppa-PDT | [89] |
GPX4 | Activator | Protective | AMC-HN2–11/SNU | Ferroptosis | |
CBS | Activator | Protective | SKOV3 and OVCA429 | Ferroptosis | [94] |
Compounds | |||||
 Brusatol | Inhibitor | Cytotoxic | SKOV3/HEC-1-A/A549 | – | [96] |
 Ailanthone | Inhibitor | Cytotoxic | A2780/CP70 | Cisplatin | [97] |
 Ascorbic acid | Inhibitor | Cytotoxic | KCL22/SR; Hela | Imatinib;cisplatin / adriamycin | |
 Apigenin | Inhibitor | Cytotoxic | BEL-7402/ADM | Doxorubicin | [100] |